OakChart

Ideaya Biosciences Inc

IDYAHealthcare·Biotechnology·USA·Mid·NASD·Nov 10 • 3:59 PM ET

31.750.00 (0.00%)
2026-11-11 14:40 CET
Market cap
3,070.05 USD m
Revenue, TTM
36.53 USD m
Net income, TTM
-420.01 USD m
Free cash flow, TTM
-349.80 USD m
EPS diluted, TTM
-4.49
P/E
-
Compare

Price

IDYA against its 20, 50 and 200-day averages
2050200beatmiss
30.0035.0040.002.1M4.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IDYAclose 31.7520-day 33.1150-day 35.95200-day 33.8831.75

25.6% under 42.68 on 25 Aug 2026. Last 15 sessions, 19.4% high to low

Profile

IDYA
52-week range, 31% of the way up
26.8142.68

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

IndexRUT
Employees145
IPOMay 23, 2019
Beta0.09
ATR, 14d1.44
Rel volume0.00
Short float9.12%
Insider own6.64%
Inst own101.52%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap3.07B
Enterprise Value2.26B
Income-420.01M
Sales36.53M
Book/sh11.30
Cash/sh8.67
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees145
IPOMay 23, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S84.04
P/B2.81
P/C3.66
P/FCF-
EV/EBITDA-
EV/Sales61.90
Quick Ratio9.04
Current Ratio9.04
Debt/Eq0.03
LT Debt/Eq0.03
Option/ShortYes / Yes

Earnings

EPS (ttm)-4.49
EPS next Y-4.36
EPS next Q-1.17
EPS this Y-268.96%
EPS next Y7.66%
EPS next 5Y-
EPS past 3/5Y3.17% 1.64%
Sales past 3/5Y62.54% 62.11%
EPS Y/Y TTM-144.53%
Sales Y/Y TTM-82.99%
EPS Q/Q-191.88%
Sales Q/Q-95.07%
EarningsNov 03 BMO
EPS/Sales Surpr.-3.43% 35.06%

Ownership

Insider Own6.64%
Insider Trans-0.56%
Inst Own101.52%
Inst Trans4.96%
ROA-34.98%
ROE-38.46%
ROIC-37.51%
Gross Margin87.67%
Oper. Margin-1267.38%
Profit Margin-1149.62%
SMA20-4.11%
SMA50-11.68%
SMA200-6.28%
Trades-

Technical

Shs Outstand96.65M
Shs Float90.27M
Short Float9.12%
Short Ratio9.34
Short Interest8.24M
52W High42.68 -25.61%
52W Low26.81 18.43%
Volatility4.23% 4.52%
ATR (14)1.44
RSI (14)40.17
Beta0.09
Rel Volume0.00
Avg Volume881.61K
Volume0

Performance

Perf Week1.34%
Perf Month-11.95%
Perf Quarter-14.10%
Perf Half Y12.91%
Perf YTD-8.16%
Perf Year2.78%
Perf 3Y8.03%
Perf 5Y39.99%
Perf 10Y-
Recom1.12
Target Price50.69
Prev Close31.75
Price31.75
Change %0.00%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 16, 2026InitiatedWWilliam BlairOutperform
Oct 14, 2026ResumedSStifelBuy$48+51.2%
Jan 07, 2026ResumedUUBSBuy$50+57.5%
Nov 24, 2025InitiatedTTruistBuy
Sep 18, 2025InitiatedGGuggenheimBuy$50+57.5%
Sep 04, 2025InitiatedCCitizens JMPMkt Outperform$41+29.1%
Sep 04, 2025InitiatedBBarclaysOverweight$40+26.0%
Jul 22, 2025InitiatedTTD CowenBuy
Jul 10, 2025ResumedGGoldmanNeutral$25-21.3%
Jun 26, 2025InitiatedWWells FargoOverweight$44+38.6%

Peers

Mkt cap
TickerCompanyMkt cap
IMCRImmunocore Holdings plc ADR1.67B
TNGXTango Therapeutics Inc4.21B
AURAAura Biosciences Inc792.01M
REPLReplimune Group Inc2.24B
RLAYRelay Therapeutics Inc4.45B
ERASErasca Inc5.26B
PBLSParabilis Medicines Inc3.71B
RVMDRevolution Medicines Inc42.18B
CELCCelcuity Inc3.38B
IOVAIovance Biotherapeutics Inc3.80B

Insider trading

7 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Hata Yujiro SPresident and CEOOct 06 '26Option Exercise4.3126,338113,517717,033Oct 08 07:03 PM
Hata Yujiro SPresident and CEOOct 06 '26Sale37.4126,338985,397690,695Oct 08 07:03 PM
YUJIRO HATACEOOct 06 '26Proposed Sale38.23230,3168,804,981Oct 06 04:13 PM
Ruiz Briseno AndresChief Accounting OfficerJul 07 '26Option Exercise12.869,550122,81336,016Jul 09 04:56 PM
Ruiz Briseno AndresChief Accounting OfficerJul 07 '26Sale40.019,550382,13126,466Jul 09 04:56 PM
Andres Ruiz BrisenoSenior VPJul 07 '26Proposed Sale40.019,550382,131Jul 07 04:54 PM
Stein JeffreyDirectorMar 02 '26Buy32.9650,0001,647,89054,281Mar 02 07:18 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 689.41B
IWMiShares Russell 2000 Index FundAUM: 78.30B
XBIState Street SPDR S&P Biotech ETFAUM: 10.53B
VXFVanguard Extended Market Index ETFAUM: 30.61B
IWNiShares Russell 2000 Value ETFAUM: 14.17B
IBBiShares Biotechnology ETFAUM: 11.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.97B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.57B
SCHASchwab U.S. Small-Cap ETFAUM: 22.32B
DFACU.S. Core Equity 2 Portfolio-ETF Class SharesAUM: 49.29B

News

latest 14 of 206
  • IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events (PR Newswire)
  • IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update (PR Newswire)
  • IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
  • IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas (PR Newswire)
  • IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma (PR Newswire)
  • Loading…
  • IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development (PR Newswire)
  • IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
  • IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma (PR Newswire)
  • IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences (PR Newswire)
  • IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer (PR Newswire)
  • IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
  • IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer (PR Newswire)
  • IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-03-1.220-1.180-1.22010.247.5815
2026Q22026-08-04-1.220-1.057-1.2228.868.0214
2026Q12026-05-05-1.110-0.989-1.1116.565.0416
2025Q42026-02-17-0.940-0.952-0.94010.886.3118
2025Q32025-11-041.466-0.8271.330207.836.3414
2025Q22025-08-05-0.880-0.782-0.8760.004.1914
2025Q12025-05-06-0.820-0.661-0.8170.002.159
2024Q42025-02-13-1.490-0.629-1.4927.005.0913
2024Q32024-11-04-0.600-0.648-0.6010.004.2712
2024Q22024-08-06-0.680-0.536-0.6770.004.4612
2024Q12024-05-07-0.530-0.510-0.5270.005.4311
2023Q42024-02-20-0.520-0.468-0.5203.928.8410
2023Q32023-11-07-0.460-0.489-0.4578.048.3811
2023Q22023-08-10-0.500-0.552-0.4963.544.8911
2023Q12023-05-09-0.490-0.541-0.4897.886.149
2022Q42023-03-07-0.500-0.555-0.5034.027.009

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-3.360-2.576-3.3590.000.00
2020FY-1.400-1.427-1.39519.5416.91
2021FY-1.410-1.228-1.41227.9433.97
2022FY-1.420-1.434-1.41550.9353.92
2023FY-1.960-1.907-1.96423.3928.28
2024FY-3.360-2.467-3.3617.004.67
2025FY-1.280-1.287-1.280218.71216.88
2026FY--4.723--45.37
2027FY--4.361--124.45
2028FY--3.565--270
2029FY--2.180--533.8
2030FY--0.211--874.42

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-09164118.850.0050.00
2026Q4S2026-11-06164118.850.0050.00
2026Q4S2026-11-04163118.770.0050.00
2026Q4S2026-11-03162118.720.0050.00
2026Q4S2026-10-28161218.470.0050.00
2026Q4S2026-10-23161218.480.0050.00
2026Q4S2026-10-20161218.480.0050.00
2026Q4S2026-10-18162218.480.0050.00
2026Q4S2026-10-16164318.480.0050.00
2026Q4S2026-10-14163318.040.0050.00
2026Q4S2026-10-12153318.630.0050.00
2026Q4S2026-09-28143319.330.0050.00
2026Q4S2026-08-28153418.040.0050.00
2026Q4S2026-08-07154318.050.0050.00

Estimate history

EPS, annual-0.586-1.698-3.359-1.395-1.412-1.415-1.964-3.361-1.285-4.494
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.601-1.492-0.817-0.8761.33-0.94-1.111-1.222-1.222
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00019.53827.94150.93123.3857218.7136.53
Period201720182019202020212022202320242025TTM
Sales, quarterly0700207.83410.8766.568.85710.242
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual20.22920.30820.33929.53738.53348.19365.03986.50487.79796.65
Period201720182019202020212022202320242025MRQ
Shares, quarterly86.35886.50487.56587.64287.66687.79787.85696.37696.65
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue36.53218.717.0023.3950.9327.9419.540.000.00
Cost of Goods Sold Incl. D&A4.504.593.834.012.101.731.381.250.89
Gross Profit32.03214.123.1719.3848.8326.2218.16-1.25-0.89
Selling, General and Administrative Excl. Other495.07373.43330.14153.81111.3376.4853.5043.0335.53
Research and Development412.59314.70294.67129.5189.5458.1639.7034.3231.75
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-463.04-159.31-326.98-134.43-62.50-50.27-35.34-44.27-36.42
Interest Expense0.000.000.000.000.000.000.000.00-
Unusual Expense0.000.000.000.000.000.000.00-0.00
Net Income Before Taxes-420.01-113.70-274.48-112.96-58.66-49.76-34.49-41.98-34.35
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-420.01-113.70-274.48-112.96-58.66-49.76-34.49-41.98-34.35
Net Income From Continuing Operations-420.01-113.70-274.48-112.96-58.66-49.76-34.49-41.98-34.35
Net Income-420.01-113.70-274.48-112.96-58.66-49.76-34.49-41.98-34.35
EPS (Recurring)-4.08-1.28-3.36-1.96-1.42-1.41-1.40-3.36-1.70
EPS (Basic, Before Extraordinaries)-4.49-1.28-3.36-1.96-1.42-1.41-1.40-3.36-1.70
EPS (Diluted)-4.49-1.28-3.36-1.96-1.42-1.41-1.40-3.36-1.70
EBITDA-458.53-154.72-323.14-130.42-60.40-48.54-33.96-43.03-35.53
Non-Operating Income (Expense)43.0245.6252.5021.473.850.510.852.302.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense60.7246.1234.7518.4911.638.243.612.170.75
Price To Sales Ratio108.2613.99299.8887.5214.7929.8317.71--
Gross Margin87.6797.9045.2382.8695.8793.8392.93--
Operating Margin-1,267.38-72.84-4,671.07-574.85-122.72-179.91-180.90--
Net Margin-1,149.62-51.99-3,921.10-483.05-115.17-178.10-176.55--
Shares Outstanding96.6587.8086.5065.0448.1938.5329.5420.3420.31
Market Capitalization3,070.053,070.052,221.302,293.47874.22910.08406.98152.48160.41

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue10.248.866.5610.88207.830.000.007.00
Cost of Goods Sold Incl. D&A1.031.131.141.201.031.231.130.64
Gross Profit9.217.725.429.68206.80-1.23-1.136.36
Selling, General and Administrative Excl. Other146.84130.01113.96104.2598.3587.5783.26150.50
Research and Development121.58108.6995.7386.6082.9974.2370.89140.18
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-137.63-122.29-108.54-94.57108.45-88.81-84.39-144.14
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-125.75-112.45-98.54-83.27119.24-77.49-72.18-130.31
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-125.75-112.45-98.54-83.27119.24-77.49-72.18-130.31
Net Income From Continuing Operations-125.75-112.45-98.54-83.27119.24-77.49-72.18-130.31
Net Income-125.75-112.45-98.54-83.27119.24-77.49-72.18-130.31
EPS (Recurring)-1.22-1.22-1.11-0.941.33-0.88-0.82-1.49
EPS (Basic, Before Extraordinaries)-1.22-1.22-1.11-0.941.35-0.88-0.82-1.49
EPS (Diluted)-1.22-1.22-1.11-0.941.33-0.88-0.82-1.49
EBITDA-136.60-121.16-107.40-93.37109.48-87.57-83.26-143.50
Non-Operating Income (Expense)11.889.8410.0111.3010.7911.3112.2113.83
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense17.7316.6614.5411.7912.2211.8710.249.48
Price To Sales Ratio108.2614.6513.1214.0011.36265.67206.75320.67
Gross Margin89.9387.2182.5888.9999.50--90.81
Operating Margin-1,343.80-1,380.73-1,654.63-869.5352.18---2,059.11
Net Margin-1,227.78-1,269.64-1,502.12-765.6657.37---1,861.60
Shares Outstanding96.6596.3887.8687.8087.6787.6487.5786.50
Market Capitalization3,070.053,543.752,925.963,030.632,384.791,840.971,433.862,221.30

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments639.39676.32525.11364.83246.77283.5898.9689.9613.16
Short Term Receivables5.970.000.020.211.101.880.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets21.3713.397.505.413.123.142.700.710.42
Total Current Assets666.73689.71532.63370.45251.00288.61101.6590.6713.58
Net Property, Plant & Equipment31.2927.748.418.998.669.489.705.153.74
Total Investments and Advances411.31406.64108.258.42121.400.111.630.110.07
Intangible Assets0.000.00----0.000.000.00
Other Assets0.000.000.030.100.290.080.020.620.09
Total Assets1,109.321,124.09649.32387.97381.35298.27113.0096.5417.48
Short Term Debt Incl. Current Port. of LT Debt0.340.301.751.871.701.541.150.000.00
Accounts Payable17.5815.426.604.282.100.950.711.420.66
Other Current Liabilities40.8930.3518.7625.5741.3636.155.094.001.77
Total Current Liabilities58.8146.0727.1031.7245.1638.646.945.412.43
Long Term Debt27.5718.871.121.613.485.185.630.003.21
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.005.1831.1956.170.031.691.49
Total Liabilities86.3964.9428.2338.5179.83100.0012.607.107.13
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00138.3926.08
Common Equity1,022.931,059.15621.09349.45301.51198.27100.40-48.95-15.74
Total Shareholders Equity1,022.931,059.15621.09349.45301.51198.27100.4089.4410.35
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity1,022.931,059.15621.09349.45301.51198.27100.4089.4410.35
Total Liabilities & Stockholders Equity1,109.321,124.09649.32387.97381.35298.27113.0096.5417.48
Book Value Per Share11.6512.249.557.257.826.714.94-2.41-0.78
Tangible Book Value Per Share11.6512.249.557.257.826.714.94-2.41-0.78
Full-Time Employees14513112410381624758-
Price to Book Ratio2.811.884.112.373.022.091.521.45-
Return on Assets-10.18-30.95-21.78-15.25-14.64-16.77-40.06-60.25-
Return on Equity-10.92-32.67-23.28-18.02-19.91-23.10-44.22-68.84-
Return on Invested Capital-10.82-25.46-18.15-16.71-16.32-16.95-39.59-38.40-87.53
Quick Ratio11.3414.9719.6511.685.567.4714.6516.755.58
Current Ratio11.3414.9719.6511.685.567.4714.6516.755.58

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-420.01-113.70-274.48-112.96-58.66-49.76-34.49-41.98-34.35
Depreciation4.494.593.834.012.101.731.381.250.89
Other Funds (Non Cash)55.7536.1411.516.9410.9310.074.171.704.19
Funds from Operations-359.77-72.97-259.13-102.02-45.62-37.97-28.94-39.03-29.27
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital12.411.8711.55-13.21-41.55-17.8184.41-0.281.65
Cash from Operating Activities-347.36-71.10-247.58-115.22-87.17-55.7855.46-39.31-27.62
Capital Expenditures-2.44-2.37-3.86-2.37-3.44-2.64-0.49-1.35-1.71
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments-53.4272.34-498.70-156.09-29.96-67.02-145.753.62-61.47
Purchase of Investments-655.55-607.89-1,191.31-595.98-255.81-315.00-242.31-88.00-133.30
Sale Or Maturity of Investments602.13680.23692.61439.89225.85247.9796.5691.6271.83
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-55.8669.98-502.56-158.46-33.40-69.67-146.242.27-63.18
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock366.2229.78677.55362.7297.17145.45128.7550.61105.38
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock366.2229.78677.55362.7297.17145.45128.7550.61105.38
Proceedsfrom Stock Options357.7926.35665.07353.1695.72143.95127.5650.32105.29
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities366.2229.78677.55362.7297.17145.45128.7550.61105.38
Net Change in Cash-37.0028.66-72.5989.04-23.4120.0137.9713.5614.58
Free Cash Flow-349.80-73.47-251.44-117.59-90.62-58.4254.97-40.67-29.33
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow------6.30--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments838.54828.96671.20639.39786.89669.74
Short Term Receivables10.2415.426.565.970.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets23.1819.6518.3521.3715.7615.86
Total Current Assets871.97864.02696.11666.73802.65685.60
Net Property, Plant & Equipment29.5830.4631.2531.2931.7232.73
Total Investments and Advances313.57415.21302.99411.31350.76322.94
Intangible Assets-0.000.000.000.000.00
Other Assets0.910.000.000.000.000.00
Total Assets1,216.021,309.701,030.351,109.321,185.141,041.27
Short Term Debt Incl. Current Port. of LT Debt2.151.190.350.340.330.32
Accounts Payable22.0430.5120.7417.5818.4317.27
Other Current Liabilities72.2250.9843.7440.8945.7537.75
Total Current Liabilities96.4182.6864.8358.8164.5155.34
Long Term Debt27.5528.1228.2527.5726.9226.28
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.001.680.00
Total Liabilities123.96110.7993.0886.3993.1081.62
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1,092.061,198.90937.271,022.931,092.03959.65
Total Shareholders Equity1,092.061,198.90937.271,022.931,092.03959.65
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1,092.061,198.90937.271,022.931,092.03959.65
Total Liabilities & Stockholders Equity1,216.021,309.701,030.351,109.321,185.141,041.27
Book Value Per Share11.3012.4410.6711.6512.4610.95
Tangible Book Value Per Share11.3012.4410.6711.6512.4610.95
Full-Time Employees---145--
Price to Book Ratio2.813.492.862.782.481.80
Return on Assets-34.98-14.89-13.14-10.18-13.26-32.93
Return on Equity-38.46-16.22-14.28-10.92-14.15-35.09
Return on Invested Capital-11.23-9.16-10.21-7.9310.66-7.86
Quick Ratio9.0410.4510.7411.3412.4412.39
Current Ratio9.0410.4510.7411.3412.4412.39

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-125.75-112.45-98.54-83.27119.24-77.49
Depreciation1.031.121.141.201.031.23
Other Funds (Non Cash)16.5215.6413.3210.2710.239.18
Funds from Operations-108.20-95.69-84.07-71.81130.51-67.08
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital14.727.488.90-18.6911.714.61
Cash from Operating Activities-93.48-88.21-75.17-90.50142.21-62.47
Capital Expenditures-0.27-0.87-0.97-0.33-0.04-0.66
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments78.92-155.07119.92-97.1941.8146.58
Purchase of Investments-63.37-313.43-42.61-236.14-138.99-127.55
Sale Or Maturity of Investments142.29158.37162.53138.94180.80174.13
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities78.65-155.93118.95-97.5341.7745.92
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock3.69359.211.182.130.301.21
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.69359.211.182.130.301.21
Proceedsfrom Stock Options-1.18358.36-0.010.63-0.080.80
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities3.69359.211.182.130.301.21
Net Change in Cash-11.14115.0744.96-185.89184.28-15.35
Free Cash Flow-93.75-89.08-76.14-90.83142.17-63.14

Revenue breakdown

Pharmaceutical Preparations2024: 7.00M 2025: 218.71M
United States2024: 7.00M 2025: 218.71M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.12%8.2M90.3M812.62K
2026-10-1510.08%9.1M90.1M789.11K
2026-09-3010.19%9.2M90.1M848.24K
2026-09-1511.03%9.9M90.1M944.50K
2026-08-3111.14%10.1M90.7M1.09M
2026-08-1411.47%10.4M90.7M1.07M
2026-07-3111.09%10.1M91.2M1.11M
2026-07-1510.65%9.6M89.9M1.16M
2026-06-3011.50%10.3M89.9M1.36M
2026-06-1511.83%10.6M89.9M1.25M
2026-05-2913.65%11.3M83.1M1.16M
2026-05-1514.10%11.7M83.0M1.17M
2026-04-3014.17%11.7M82.6M1.18M
2026-04-1512.79%10.6M82.6M1.14M
2026-03-3111.81%9.8M82.6M921.86K
2026-03-1311.77%9.7M82.6M887.83K
2026-02-2711.78%9.7M82.6M901.91K
2026-02-1312.10%10.0M82.6M913.87K
2026-01-3011.12%9.3M83.8M925.10K
2026-01-1510.39%8.7M83.8M1.03M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call17.5012.5017.000.005.0160.000.000.986-0.0190.002
call20.0010.0014.500.004.3700.000.000.983-0.0180.002
call22.507.5012.000.003.6420.000.000.978-0.0180.003
call25.004.509.300.002.8540.000.000.823-0.1320.014
call27.502.707.000.002.3050.000.000.771-0.1150.016
call30.001.254.902.851.96146.000.000.646-0.1310.019
call32.500.102.501.251.35532.001.000.522-0.1780.021
call35.000.050.400.250.68165.001.000.210-0.0530.015
call37.500.000.650.150.95259.0010.000.163-0.0630.013
call40.000.004.900.201.19543.000.000.162-0.0780.013
call42.500.000.750.641.41712.000.000.151-0.0850.013
call45.000.000.100.451.09119.000.000.044-0.0260.005
call47.500.000.500.301.22712.000.000.040-0.0270.005
call50.000.004.900.501.3862.000.000.037-0.0300.004
call55.000.004.900.551.6216.000.000.032-0.0310.004
put17.500.004.900.003.5920.000.00-0.093-0.1580.009
put20.000.004.900.002.9780.000.00-0.113-0.1510.010
put22.500.000.050.002.3810.000.00-0.143-0.1410.012
put25.000.004.900.001.9280.000.00-0.170-0.1290.014
put27.500.004.100.001.4090.000.00-0.229-0.1120.016
put30.000.001.800.601.13114510.00-0.354-0.1280.019
put32.500.104.902.002.1681510.00-0.478-0.1740.021
put35.001.506.002.801.9323.000.00-0.790-0.0490.015
put37.503.608.003.802.0414.000.00-0.837-0.0590.013
put40.006.0010.506.802.3424.000.00-0.861-0.0650.012
put42.508.7013.000.002.6070.000.00-0.877-0.0710.011
put45.0011.2015.500.002.8450.000.00-0.957-0.0240.005
put47.5013.7018.000.003.0600.000.00-0.961-0.0240.004
put50.0016.2020.500.003.2580.000.00-0.964-0.0250.004
put55.0021.2025.500.003.6110.000.00-0.968-0.0260.004

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-03S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-038-KCurrent report2026-11-03SEC
2026-10-084Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-06144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13GSEC
2026-08-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-07-31SCHEDULE 13GSEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-07144Filing for proposed sale of securities under Rule 144.SEC
2026-06-238-KCurrent report2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-108-KCurrent report2026-06-08SEC
2026-06-09424B5SEC
2026-06-08424B5SEC
2026-06-053Initial statement of beneficial ownership of securities2026-03-18SEC
2026-06-038-KCurrent report2026-06-03SEC
2026-06-018-KCurrent report2026-06-01SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-058-KCurrent report2026-05-05SEC
2026-05-05424B5SEC
2026-05-05S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-05-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-058-KCurrent report2026-05-05SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1000985.40K1
2026-090000
2026-080000
2026-0700382.13K1
2026-060000
2026-050000
2026-040000
2026-031.65M100
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC15.00%
BlackRock, Inc.9.35%
Jupiter Topco LLC9.02%
Capital Research Global Investors5.62%
BAKER BROS. ADVISORS LP5.27%
STATE STREET CORP4.78%
VANGUARD CAPITAL MANAGEMENT LLC4.35%
Logos Global Management LP3.16%
ADAGE CAPITAL PARTNERS GP, L.L.C.2.86%
DEERFIELD MANAGEMENT COMPANY, L.P.2.85%

Funds

Fund% owned
SMALLCAP World Fund Inc5.47%
Fidelity Growth Company Fund4.90%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.12%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.43%
iShares Russell 2000 ETF2.26%
Fidelity Growth Company K6 Fund1.40%
Fidelity Series Growth Company Fund1.14%
Janus Henderson Triton Fund1.13%
VANGUARD EXTENDED MARKET INDEX FUND1.10%
Fidelity Small Cap Index Fund0.96%

OakChart. IDYA. Cached 15 minutes.